Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bimekizumab versus secukinumab in adults with moderate to severe chronic plaque psoriasis
NL-OMON55812Phase 3Active, not recruiting
- Sponsor
- UCB
- Start
- Apr 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of bimekizumab in psoriasis, sponsored by UCB. Primary endpoint: PASI100 response at Week 16. Started Apr 2019; status: active, not recruiting.
02
Drugs
bimekizumab
03
Conditions
psoriasis
Beyond the preview
Go deeper on NL-OMON55812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55812.